Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: A prospective cohort study

The Lancet HIV

Volumn 2, Issue 7, 2015, Pages e279-e287

  Noguchi, L M ^a   Richardson, B A ^b   Baeten, J M ^b   Marrazzo, J M ^b   Hillier, S L ^c,d   Bunge, K ^c,d   Balkus, J E ^e   Chirenje, Z M ^f   Ramjee, G ^g   Nair, G ^h   Palanee Phillips, T ⁱ   Selepe, P ^j   Van der Straten, F ^k   Parikh, U M ^l   Gomez, K ^m   Piper, J M ⁿ   Watts, D H ^o  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Department of Biostatistics ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UZ UCSF Collaborative Research Programme   (Zimbabwe)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j AURUM INSTITUTE   (South Africa)

^k RTI INTERNATIONAL   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m FAMILY HEALTH INTERNATIONAL   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o U S DEPARTMENT OF STATE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; PLACEBO; TENOFOVIR; CONTRACEPTIVE AGENT; NORETHISTERONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONDOM USE; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNDING; HERPES SIMPLEX VIRUS 2; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SOUTH AFRICA; YOUNG ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADULT; COHORT STUDIES; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MEDROXYPROGESTERONE ACETATE; NORETHINDRONE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOUTH AFRICA; TENOFOVIR; YOUNG ADULT;

EID: 84944228695     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00058-2     Document Type: Article

References (41)

1. Ahmed S, Li Q, Liu L, Tsui AO. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet 2012; 380: 111-25.
2. Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet 2012; 380: 149-56.
3. Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90: 360-90.
4. WHO. Hormonal contraception and HIV: technical statement, 16 February 2012. http://whqlibdoc.who.int/hq/2012/WHO_ RHR_12.08_eng.pdf (accessed April 29, 2014).
5. WHO. Programmatic and research considerations for hormonal contraception for women at risk of HIV and women living with HIV. 2012. http://whqlibdoc.who.int/hq/2012/WHO_RHR_12.09_ eng.pdf (accessed May 9, 2014).
6. WHO. Hormonal contraceptive methods for women at high risk of HIV and living with HIV: 2014 guidance statement. Geneva: World Health Organization, 2014.
7. UNAIDS. Getting to zero: HIV in eastern & southern Africa. 2013. http://www.unicef.org/esaro/Getting-to-Zero-2013.pdf (accessed July 15, 2014).
8. UNAIDS. HIV and AIDS estimates. 2013. http://www.unaids.org/ en/regionscountries/countries/southafrica (accessed May 14, 2014).
9. Department of Health, Republic of South Africa. National contraception and fertility planning policy and service delivery guidelines. Pretoria: Department of Health, 2012.
10. UNFPA. World contraceptive patterns. Geneva: United Nations Population Fund, 2013.
11. Department of Health, Medical Research Council, OrcMacro. South Africa Demographic and Health Survey 2003. Pretoria: Department of Health, 2007.
12. IPFF. Directory of hormonal contraceptives. 2014. http:// contraceptive.ippf.org/search (accessed May 9, 2014).
13. Pfi zer. Product monograph: DEPO-PROVERA: medroxyprogesterone acetate injectable suspension. http://www. pfi zer.ca/en/our_products/products/monograph/181 (accessed March 23, 2014).
14. Malahyde Information Systems. Nur-Isterate. http://home.intekom. com/pharm/schering/nur-ist.html (accessed May 14, 2014).
15. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169-78.
16. WHO. Medical eligibility criteria for contraceptive use. Geneva: World Health Organization, 2010.
17. Garza-Flores J, Cardenas S, Rodriguez V, Cravioto MC, Diaz-Sanchez V, Perez-Palacios G. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception 1985; 31: 361-66.
18. Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol 1991; 40: 697-704.
19. Tomasicchio M, Avenant C, Du Toit A, Ray RM, Hapgood JP. The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor. PloS One 2013; 8: e62895.
20. Huijbregts RP, Michel KG, Hel Z. Eff ect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception 2014; 90: 123-29.
21. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15: 181-89.
22. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data metaanalysis. PLoS Med 2015; 12: e1001778.
23. Polis CB, Westreich D, Balkus JE, Heff ron R. Assessing the eff ect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS 2013; (suppl 1): S35-43.
24. Aklilu M, Messele T, Tsegaye A, et al. Factors associated with HIV-1 infection among sex workers of Addis Ababa, Ethiopia. AIDS 2001; 15: 87-96.
25. Cates W, for the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Consortium. Research on hormonal contraception and HIV. Lancet 2014; 383: 303-04.
26. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372: 509-18.
27. WHO. Selected practice recommendations for contraceptive use: 2008 update. http://whqlibdoc.who.int/hq/2008/WHO_ RHR_08.17_eng.pdf (accessed May 19, 2014).
28. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-64.
29. Lutalo T, Musoke R, Kong X, et al. Eff ects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS 2013; 27 (suppl 1): S27-34.
30. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21: 85-95.
31. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21: 1771-77.
32. Heff ron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12: 19-26.
33. McCoy SI, Zheng W, Montgomery ET, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013; 27: 1001-09.
34. Noguchi L, Marrazzo J, Richardson BA, et al. Injectable progestin contraception and chlamydia and gonorrhea acquisition among South African women in VOICE. Sex Transm Dis 2014; 41: 8.
35. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000; 151: 939-45.
36. Smit J, Gray A, McFadyen L, Zuma K. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Serv Res 2001; 1: 4.
37. Morroni C, Myer L, Moss M, Hoffman M. Preferences between injectable contraceptive methods among South African women. Contraception 2006; 73: 598-601.
38. IPPF. IPPF medical bulletin: comparing injectable contraceptives. http://www.ippf.org/sites/default/fi les/tks_medbulletin_july13_ en.pdf (accessed May 13, 2014).
39. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41: 381-90.
40. Carr B, Gates MF, Mitchell A, Shah R. Giving women the power to plan their families. Lancet 2012; 380: 80-82.
41. Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG 2012; 119: 1067-73.